NIDA Clinical Trials Network: New York Node

Jennifer McNeely, MPI (NYU)
Edward Nunes, MPI (Columbia)
Clinical Trials Network (CTN)

Provides an enterprise in which NIDA, treatment researchers, and community-based service providers work toward new treatment options in community-level clinical practice.

NIDA Clinical Trials Network

- Established in 1999
- Mission to improve addiction treatment nationally using science as the vehicle

CTN’s research focus

https://nida.nih.gov/about-nida/organization/cctn/ctn/research-studies

• Over 150 funded studies
• Primarily rigorous multi-site clinical trials
• Testing new treatment models, behavioral therapies, and medications
• Improving the reach of evidence-based treatment across diverse treatment settings and participants
  • Community SUD treatment programs
  • Medical settings: primary care, ED, hospital
  • Evolving focus on minoritized and underserved populations, community-based work
• Provide a platform for related studies and training new investigators
CTN Structure

NIDA Center for Clinical Trials Network (CCTN)

Clinical Coordinating Center (CCC): The Emmes Company

Data and Statistics Center (DSC): The Emmes Company

16 Nodes – Each working with community and academic partners

New York Node
CTN New York Node

• One of the first CTN nodes, est. 2000
• Based at NYU and Columbia
• NYU MPI John Rotrosen – transitioned to Jennifer McNeely in July 2023
• Columbia MPIs Edward Nunes + Aimee Campbell
• Largest node in the network currently
• Lead node for 24+ trials
How does research happen in the CTN?

- Node provides basic infrastructure
- Individual studies funded through supplements
- The Node may lead or participate in studies
- Node works with investigators to develop and submit study concepts
- Concepts are reviewed by CTN Research Development Committee (monthly meeting)
- Funding decisions are based on CTN/NIDA priorities
Current studies in the CTN NY Node

• CTN-0096: Culturally Centering the Delivery of Medications for Opioid Disorder with AI/AN Communities (Tribal MOUD) – Venner, Campbell

• CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) - Nunes, Weiss, Rotrosen

• CTN-0101: Subthreshold OUD Prevention Trial (STOP) - McNeely & Liebschutz

• CTN-0112: Optimal Policies to Improve Methadone Maintenance Adherence Long-Term (OPTIMMAL) – Williams & Krawczyk

• CTN-0125: Integrative Data Analysis of CTN Studies to Examine the Impact of Psychosocial Treatments for Black People who use Cocaine – Burlew & Ruglass

• CTN-0126: Longitudinal Follow-up of Individuals with OUD – Hefner, McHugh, Shulman

• CTN-0139: Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care) – McNeely & Liebschutz
CTN Special Interest Groups (SIGs)

- American Indian/Alaska Native (AIAN) SIG
- Comorbidities SIG
- Gender SIG
- Minority Interest Group (MIG)
- Primary Care SIG
- Rural SIG
- Telehealth & Telemedicine SIG
- Translation and Implementation SIG
- Youth SIG

For more information: https://ctnlibrary.org/resources/sigs/
Aims of next grant cycle (2025-2032)

1. Broaden the reach of SUD services to diverse populations, through low-barrier and community-based treatment models

2. Integrate evidence-based addiction treatment in healthcare settings

3. Increase SUD treatment effectiveness by addressing mental health comorbidities and polysubstance use

4. Investigate novel treatments, including medications and digital therapeutics

5. Use existing data to study interventions in real-world care settings and inform new research questions

6. Train the next generation of addiction researchers
Thank you

Supporting text and contact information

NYU Langone Health